Drugs giant GSK set to sell rare diseases business to step up efficiency drive

Drugs giant GSK set to sell rare diseases business to step up efficiency drive
 

The company will cut more than 30 pre-clinical and clinical programmes that are “unlikely to generate sufficient returns” and allocate 80 per cent of its research and development spending to respiratory and HIV/infectious diseases, along with two potential therapy areas of oncology and immuno-inflammation. 
It is ending collaboration with Johnson & Johnson over rheumatoid arthritis drug sirukumab and will phase out support for diabetes treatment Tanzeum. 
A review of its rare diseases unit has been undertaken and “options are being considered for future ownership of these assets”. ... read more

 
27 July 2017 in Business, Views: 46
Share:
  •  




    News Widget for Webmasters


    Realtime News

     

    «
    »
    Mo Tu We Th Fr Sa Su
            1 2 3
    4 5 6 7 8 9 10
    11 12 13 14 15 16 17
    18 19 20 21 22 23 24
    25 26 27 28 29 30 31